A combination AIDS vaccine approach consisting of priming with adenovirus-HIV-1MN gp160 recombinants followed by boosting with HIV-1SF2 gp120 was evaluated in chimpanzees. Long-lasting protection, requiring only three immunizations, was achieved against a low-dose challenge with the SF2 strain of HIV-1 and a subsequent high-dose SF2 challenge administered 1 year later without an intervening boost. Notably, neutralizing antibody responses against both clinical and laboratory isolates developed in three chimpanzees and persisted until the time of high-dose challenge. The possibility that cytotoxic T-lymphocytes contribute to low-dose protection of a chimpanzee lacking neutralizing antibodies is suggested. Our results validate the live vector priming/subunit booster approach and should stimulate interest in assessing this combination vaccine approach in humans.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1038/nm0697-651 | DOI Listing |
Am J Clin Dermatol
January 2025
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02115, USA.
Individualized neoantigen-directed therapy represents a groundbreaking approach in melanoma treatment that leverages the patient's own immune system to target cancer cells. This innovative strategy involves the identification of unique immunogenic neoantigens (mutated proteins specific to an individual's tumor) and the development of therapeutic vaccines that either consist of peptide sequences or RNA encoding these neoantigens. The goal of these therapies is to induce neoantigen-specific immune responses, enabling the immune system to recognize and destroy cancer cells presenting the targeted neoantigens.
View Article and Find Full Text PDFHum Vaccin Immunother
December 2025
Department of Oncology, Changzhi People's Hospital Affiliated to Changzhi Medical College, Changzhi, Shanxi, China.
Human epidermal growth factor receptor 2 (HER2) is a critical biomarker and therapeutic target in gastric/gastroesophageal junction (G/GEJ) cancers, despite the initial success of HER2-targeted therapies, such as trastuzumab, resistance to these drugs has emerged as a major impediment to effective long-term treatment. This review examines the mechanisms of drug resistance in HER2-positive G/GEJ cancer, the primary mechanisms of resistance explored include alterations in the HER2 receptor itself, such as mutations and changes in expression levels, as well as downstream signaling pathways, and interactions with the tumor microenvironment (TME). Furthermore, the review discusses the Novel therapeutic approaches, including the use of antibody-drug conjugates (ADCs) and combination therapies are assessed for their potential to enhance outcomes.
View Article and Find Full Text PDFPLoS One
January 2025
Department of Mathematics, College of Natural and Computational Science, Debre Berhan University, Debre Berhan, Adis Ababa, Ethiopia.
Tuberculosis (TB) is one of the deadly infectious diseases affecting millions of individuals throughout the world. The main objective of this study is to investigate the impact of media coverage on the transmission dynamics of TB with vaccine and treatment strategy using mathematical model analysis. In the qualitative analysis of the proposed model we proved the existence, uniqueness, positivity, and boundedness of the model solutions, investigated both the disease-free and endemic equilibrium points, computed the basic and effective reproduction numbers using next generation matrix approach, analyzed the stability analysis of the equilibrium points, the backward bifurcation using the Castillo-Chavez and Song theorem and we re-formulated the corresponding optimal control problem and analyzed by applying the Pontryagin's Minimum Principle.
View Article and Find Full Text PDFAsian Pac J Cancer Prev
January 2025
Parul Institute of Applied Sciences, Parul University, Vadodara, India.
Background: Breast cancer remains a significant global health challenge, requiring innovative therapeutic strategies. In silico methods, which leverage computational tools, offer a promising pathway for vaccine development. These methods facilitate antigen identification, epitope prediction, immune response modelling, and vaccine optimization, accelerating the design process.
View Article and Find Full Text PDFAsian Pac J Cancer Prev
January 2025
Experimental Therapy Department, Iraqi Center for Cancer and Medical Genetic Research. Mustansiriyah University, Baghdad, Iraq.
Background: The use of bacterial vaccines as a potential Bacterial-Based Cancer Therapy (BBCT) presents an innovative approach, transforming these vaccines into multifunctional tools capable of serving dual roles in medicine.
Materials And Methods: This study aimed to conduct in vitro, immunity-independent experiments to investigate the anticancer properties of vaccine-derived bacterial toxoids on various cancer cell lines. Six concentrations of the DTP vaccine (5 x 10-4, 25 x 10-5, 125 x 10-6, 625 x 10-7, 312 x 10-7, and 15 x 10-6 µg/ml) were tested on two cancer cell lines (SKG and HCAM) and a normal Rat Embryonic Fibroblast (REF) cell line.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!